What compounds affect the Phase II - Conjugation of compounds pathway?

268 compounds in the BiohacksAI corpus have documented interactions with genes in the Phase II - Conjugation of compounds pathway (Reactome ID: R-HSA-156580). These compounds target 13 genes within this pathway.

What genes are in the Phase II - Conjugation of compounds pathway?

The Phase II - Conjugation of compounds pathway involves 13 genes. Key genes include: AHCY, CYP1A2, GSTK1, GSTO1, GSTP1, NNMT, UGT1A1, UGT1A10, UGT1A3, UGT1A4.

Phase II - Conjugation of compounds

REACTOME PATHWAY

Reactome: R-HSA-15658013 genes268 compounds

The Phase II - Conjugation of compounds pathway (Reactome ID: R-HSA-156580) involves 13 genes and is affected by 268 compounds in the BiohacksAI evidence corpus. Compound-pathway associations are derived from target overlap: a compound is linked to this pathway if it targets ≥2 genes within the pathway.

Genes in this Pathway

AHCY CYP1A2 GSTK1 GSTO1 GSTP1 NNMT UGT1A1 UGT1A10 UGT1A3 UGT1A4 UGT1A6 UGT1A9 UGT2B7

Compounds Affecting Phase II - Conjugation of compounds

#	Compound	Targets Hit	Studies
1	scutellarein	—	113
2	myricetin-3-O-galactopyranoside [Supplementary Concept]	—	300
3	Edaravone	—	298
4	Quercetin	—	300
5	Disulfiram	—	297
6	Pueraria	—	300
7	Luteolin 5,7,3',4'-tetrahydroxy-flavone,	—	150
8	Emodin Purgative anthraquinone found in several plants, especially RHAMNUS PURSHIANA. It was formerly used as	—	300
9	Vitamin K 3	—	300
10	tyrphostin ag 1478	—	4
11	Methylene Blue	—	200
12	Anastrozole	—	298
13	Zearalenone (S-(E))-3,4,5,6,8,10-Hexahydro-14,16-dihydroxy-3-methyl-1H-2-benzoxacyclotetradec in-1,7(8H)-dione.	—	300
14	Chlorhexidine	—	299
15	Iodoacetamide	—	300
16	Aurintricarboxylic Acid	—	184
17	Cisplatin	—	300
18	Dequalinium	—	136
19	Ethinyl Estradiol	—	300
20	Guanabenz	—	298
21	ketoconazole	—	299
22	propionylpromazine hydrochloride	—	2
23	Suramin	—	300
24	tyrphostin 9	—	2
25	Amitriptyline Tricyclic antidepressant with anticholinergic and sedative properties. It appears to prevent	—	299
26	Mycophenolic Acid Compound derived from Penicillium stoloniferum and related species. It blocks de novo biosynthesis of purine nucleotides by inhibition of	—	300
27	Calcimycin	—	216
28	Thyroxine	—	994
29	Thyroxine	—	300
30	celastrol	—	300
31	Phenacetin	—	300
32	Apigenin 5,7,4'-trihydroxy-flavone,	—	300
33	Melatonin	—	297
34	chrysin	—	300
35	Flutamide	—	298
36	Genistein	—	300
37	Kaempferols	—	300
38	Clotrimazole	—	296
39	Methoxsalen	—	300
40	Piribedil	—	300
41	Riluzole	—	298
42	Sulindac	—	297
43	Thiabendazole 2-Substituted benzimidazole first introduced in 1962. It is active against	—	299
44	Isoniazid Antibacterial agent used primarily as	—	299
45	Leflunomide	—	297
46	Nocodazole Nocodazole is	—	215
47	Clofibrate	—	299
48	Diuron	—	300
49	Ethoxyquin Antioxidant; also	—	180
50	Secologanin Tryptamine Alkaloids Compounds formed by condensation of secologanin with tryptamine resulting in	—	300

About the Phase II - Conjugation of compounds Pathway

The Phase II - Conjugation of compounds pathway is catalogued in Reactome (ID: R-HSA-156580) and involves 13 genes. In the BiohacksAI corpus, 268 compounds have documented interactions with at least 2 genes in this pathway, establishing mechanistic relevance. Key pathway genes include AHCY, CYP1A2, GSTK1, GSTO1, GSTP1.